Advances in pharmacotherapy for allergic conjunctivitis

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 8, 2015, Pages 1219-1231

  Abelson, Mark B ^a,b   Shetty, Sirikishan ^c   Korchak, Michael ^c   Butrus, Salim I ^d   Smith, Lisa M ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Ora Inc ^*  (United States)

^c GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allergic conjunctivitis; Antihistamine; Mast cell stabilizer; Ocular allergy

Indexed keywords

ALLERGEN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; DECONGESTIVE AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE RELEASE INHIBITOR; HORMONE RECEPTOR STIMULATING AGENT; IMMUNOMODULATING AGENT; ISUNAKINRA; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOTRANSFERASE INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; ANTIALLERGIC AGENT;

ALLERGIC CONJUNCTIVITIS; ALLERGIC REACTION; CORTICOSTEROID THERAPY; DESENSITIZATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; META ANALYSIS (TOPIC); NONHUMAN; PHARMACEUTICAL CARE; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; CONJUNCTIVITIS, ALLERGIC; DRUG EFFECTS; IMMUNOLOGY; MAST CELL; PATHOLOGY;

ADRENAL CORTEX HORMONES; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONJUNCTIVITIS, ALLERGIC; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOMODULATION; MAST CELLS;

EID: 84929167622     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1040760     Document Type: Review

References (101)

1. Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol 2010;126(4):778-83
2. Abelson MB. editor. Allergic disease of the eye. WB Saunders Co; Philadelphia: 2001
3. La Rosa M, Lionetti E, Reibaldi M, et al. Allergic conjunctivitis: a comprehensive review of the literature. Ital J Pediatr 2013;39:18
4. Gomes PJ. Trends in prevalence and treatment of ocular allergy. Curr Opin Allergy Clin Immunol 2014;14:451-6
5. O'Brien TP. Allergic conjunctivitis: an update on diagnosis and management. Curr Opin Allergy Clin Immunol 2013;13(5):543-9
6. Abelson MB, Yamamoto GK, Allansmith MR. Effects of ocular decongestants. Arch Ophthalmol 1980;98:856-8
7. Abelson MB, Butrus SI, Weston JH, et al. Tolerance and absence of rebound vasodilation following topical ocular decongestant usage. Ophthalmology 1984;91(11):1364-7
8. Adamczyk DT, Jaanus SD. Anti-allergy drugs and decongestants. In: Bartlett JD, editor. Clinical ocular pharmacology. 5th edition. Elsevier; St. Louis, MO: 2008. p. 245-60
9. Vaidyanathan S, Williamson P, Clearie K, et al. Fluticasone reverses oxymetazoline induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med 2010;182(1):19-24
10. Butrus S, Portela R. Ocular allergy: diagnosis and treatment. Ophthalmol Clin N Am 2005;18:485-92
11. Mantelli F, Calder VL, Bonini S. The anti-inflammatory effects of therapies for ocular allergy. J Ocul Pharmacol Ther 2013;29(9):786-93
12. Weston JH, Udell IJ, Abelson MB. H1 receptors in the human ocular surface. Invest Ophthalmol Vis Sci 1981;20(Suppl):100
13. Abelson MB, Udell IJ. H2 receptors in the human ocular surface. Arch Ophthalmol 1981;99(2):302-4
14. Leonardi A, DiStefano A, Vicari C, et al. Histamine H4 receptors in normal conjunctiva and in vernal keratoconjunctivitis. Allergy 2011;66(10):1360-6
15. Ohbayashi M, Manzouri B, Morohoshi K, et al. The role of histamine in ocular allergy. Adv Exp Med Biol 2010;709:43-52
16. Leonardi A. Allergy and allergic mediators in tears. Exp Eye Res 2013;106:106-117
17. Leonardi A, DeFranchis G, DePaoli M, et al. Histamine-induced cytokine production and ICAM-1 expression in human conjunctival fibroblasts. Curr Eye Res 2002;25:189-96
18. Huang JF, Thurmond RL. The new biology of histamine receptors. Curr Allergy Asthma Rep 2008;8:21-7
19. Abelson MB, McLaughlin JT, Gomes PJ. Antihistamines in ocular allergy: are they all created equal? Curr Allergy Asthma Rep 2011;11:205-11
20. Abelson MB, Paradis A, George MA, et al. Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis. Arch Ophthalmol 1990;108:520-4
21. Mishra GP, Tamboli V, Jwala J, et al. Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis. Recent Pat Inflamm Allergy Drug Discov 2011;5(1):26-36
22. Abelson MB, George MA, Schaefer K, et al. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis. J Allergy Clin Immunol 1994;94(3 Pt 1):458-64
23. Verin P, Easty DL, Secchi A, et al. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. Am J Ophthalmol 2001;131(6):691-8
24. Miraldi Utz V, Kaufman AR. Allergic eye disease. Pediatr Clin Am 2014;61:607-20
25. Solomon A, Pe'er J, Levi-Schaffer F. Advances in ocular allergy: Basic mechanisms, clinical patterns and new therapies. Curr Opin Allergy Clin Immunol 2001;1:477-82
26. Yanni JM, Miller ST, Gamache DA, et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol 1997;79(6):541-5
27. Santos CI, Huang AJ, Abelson MB, et al. Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. Am J Ophthalmol 1994;117(4):488-97
28. Abelson MB, Berdy GJ, Mundorf T, et al. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebocontrolled phase III studies. J Ocul Pharmacol Ther 2002;18(5):475-88
29. Leonardi A. The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Curr Allergy Asthma Rep 2002;2:325-31
30. Bielory BP, Perez VL, Bielory L. Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2010;10(5):469-77
31. Druilhe A, Letuve S, Pretolani M. Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis 2003;8:481-95
32. Baiula M, Sparta A, Bedini A, et al. Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist. Mol Vis 2011;17:3208-23
33. Fukui H. Progress in allergy signal research on mast cells: up-regulation of histamine signal-related gene expression in allergy model rats. J Pharmacol Sci 2008;106:325-31
34. Chambless SL, Trocme S. Developments in ocular allergy. Curr Opin Allergy Clin Immunol 2004;4:431-4
35. Wolthers OD. Growth suppression caused by corticosteroid eye drops. J Pediatr Endocrinol Metab 2011;24(5-6):393-4
36. Dell SJ, Lowry GM, Northcutt JA, et al. A randomized, double-masked, placebocontrolled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol 1998;102:251-5
37. Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology 1999;106:362-9
38. Ilyas H, Slonim CB, Braswell GR, et al. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 2004;30:10-13
39. McGrath M, Blizzard C, Desai A, et al. In vivo drug delivery of low solubility corticosteroids from bioresorbable hydrogel, punctum plugs ARVO Annual Meeting; 2014
40. Holsclaw DS, Whitcher JP, Wong IG, et al. Supra-tarsal injection of corticosteroid in the treatment of refractory vernal keratoconjunctivitis. Am J Ophthalmol 1996;121:243-9
41. Saini JS, Gupta A, Pandey SK, et al. Efficacy of supratarsal dexamethasone versus triamcinolone injection in recalcitrant vernal keratoconjunctivitis. Acta Ophthalmol Scand 1999;77:515-18
42. Singh S, Pal V, Dhull CS. Supratarsal injection of corticosteroids in the treatment of refractory vernal keratoconjunctivitis. Indian J Ophthalmol 2001;49:241-5
43. Zaouali S, Kahloun R, Attia S, et al. Supratarsal injection of triamcinolone acetonide and childhood allergic keratoconjunctivitis. Int Ophthalmol 2012;32(2):99-106
44. Lightman S, Scadding G. Should intranasal corticosteroids be used for the treatment of ocular symptoms of allergic rhinoconjunctivitis? A review of their efficacy and safety profile. Int Arch Allergy Immunol 2012;158:317-25
45. Naclerio R. Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis. Otolaryngol Head Neck Surg 2008;138:129-39
46. Callebaut I, Vandewalle E, Hox V, et al. Nasal corticosteroid treatment reduces substance P levels in tear fluid in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 2012;109:141-6
47. Igarashi T, Nakazato Y, Kunishige T, et al. Mometasone furoate nasal spray relieves the ocular symptoms of seasonal allergic rhinoconjunctivitis. J Nippon Med Sch 2012;79:182-9
48. Naclerio R, Kaiser H, Lumry W, et al. Fluticasone furoate nasal spray provided 24-hour relief of nasal and ocular symptoms of seasonal allergic rhinitis (SAR) caused by ragweed. Allergy 2007;62:134
49. Bernstein DI, Levy AL, Hampel FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004;34:952-7
50. Moller C, Ahlstrom H, Henricson KA, et al. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 2003;33:816-22
51. Bielory L, Chun Y, Bielory BP, et al. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis. Allergy 2011;66:686-93
52. Spangler DL, Abelson MB, Ober A, et al. Randomized, double-masked comparison of Olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther 2003;25(8):2245-67
53. Blaho K. Non-steroidal antiinflammatory drugs: Current trends in pharmacology and therapeutics. J Am Optom Assoc 1992;63:875-8
54. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010;55:108-33
55. Yaylali V, Demirlenk I, Tatlipinar S, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scan 2003;81:378-82
56. Portmann A, Guedry J, Boidin-Lebel H, et al. Corneal melt associated with topical indomethacin use. J Fr Ophthalmol 2012;35(1):72-3
57. Khalifa YM, Mifflin MD. Keratitis and corneal melt with ketorolac tromethamine after conductive keratoplasty. Cornea 2011;30(4):477-8
58. Prasher P. Acute corneal melt associated with topical bromfenac use. Eye Contact Lens 2012;38(4):260-2
59. Abelson MB, Welch DL. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand Suppl 2000;60-3
60. Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a doublemasked, placebo-and active-controlled trial. Clin Ther 2003;25:1975-97
61. Ousler GW 3rd, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine, and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther 2007;29:611-16
62. Bartra J, Mullol J, Montoro J, et al. Effect of bilastine upon the ocular symptoms of allergic rhinoconjunctivitis. J Invest Allergol Clin Immunol 2011;21(Suppl 3):24-33
63. Bertelmann E, Pleyer U. Immunomodulatory therapy in ophthalmology-Is there a place for topical application? Ophthalmologica 2004;218:359-67
64. Fukushima A, Yamaguchi T, Ishida W, et al. Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions. Clin Exp Ophthalmol 2006;34:347-53
65. Shii D, Nakagawa S, Yoshimi M, et al. Inhibitory effects of cyclosporine A eye drops on symptoms in late phase and delayed-type reactions in allergic conjunctivitis models. Biol Pharm Bull 2010;33:1314-18
66. Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol 2012;30:177-84
67. Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther 2009;25:365-72
68. Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroiddependent atopic keratoconjunctivitis. Ophthalmology 1998;105:1715-20
69. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 1987;40:1256-65
70. Ohashi Y, Ebihara N, Fujishima H, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther 2010;26:165-74
71. Ryu EH, Kim JM, Laddha PM, et al. Therapeutic effect of 0.03% tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis. Korean J Ophthalmol 2012;26(4):241-7
72. Canonica GW, Ciprandi G, Petzold U, et al. Topical azelastine in perennial allergic conjunctivitis. Curr Med Res Opin 2003;19:321-9
73. Pacharn P, Vichyanond P. Immunomodulators for conjunctivitis. Curr Opin Allergy Clin Immunol 2013;13:550-7
74. Tsujii T, Yamamoto E, Ohira T, et al. Antihistamine effects on prefrontal cortex activity during working memory process in preschool children: a near-infrared spectroscopy (NIRS) study. Neurosci Res 2010;67:80-5
75. Torkildsen GL, Williams JI, Gow JA, et al. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. Ann Allergy Asthma Immunol 2010;105:57-64
76. Gallois-Bernos AC, Thurmond RL. Alcaftadine, a new antihistamine with combined antagonist activity at histamine H1, H2, and H4 receptors. J Receptor, Ligand, Channel Res 2012;5:9-20
77. Ono SJ, Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Design Develop Ther 2011;5:77-84
78. Ackerman S, D'Ambrosio FD, Greiner JV, et al. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model. J Asthma and Allergy 2013;6:43-52
79. McLaurin EB, Marsico NP, Ackerman SL, et al. Ocular itch relief with alcaftadine 0.25% versus Olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials. Adv Ther 2014;31:1059-71
80. Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope 2014;124(3):616-27
81. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40
82. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45
83. Calderon MA, Penagos M, Sheikh A, et al. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy 2011;41:1263-72
84. Rhinitis, Allergic, Perennial. CenterWatch. 2014. Available from: https://www. centerwatch.com/clinical-trials/results/ new-therapies/nmt-details.aspx? CatID=804 [Last accessed 1 April 2015]
85. De Bosscher K. Selective Glucocorticoid receptor modulators. J Steroid Biochem Mol Biol 2010;120:96-104
86. Stahn C, Lowenberg M, Hommes DW, et al. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007;275:71-8
87. Lowenberg M, Stahn C, Hommes DW, et al. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 2008;73:1025-9
88. Kato M, Hagiwara Y, Oda T, et al. Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases. J Ocular Pharm and Ther 2011;27:353-60
89. Evans RM. Molecular characterization of the glucocorticoid receptor. Recent Prog Horm Res 1989;45:1-27
90. Schacke H, Rehwinkel H. Dissociated glucocorticoid receptor ligands. Curr Opin Investig Drugs 2004;5:524-8
91. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin 1992;10:505-12
92. Spaeth GL, Rodrigues MM, Weinreb S. Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure. B. Histopathological aspects. Trans Am Ophthalmol Soc 1977;75:353-81
93. Cavet ME, Volhejn S, Harrington KL, et al. Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts and epithelial cells. Mol Vis 2013;19:1515-25
94. Redfern RL, McDermott AM. Toll-like receptors in ocular surface disease. Exp Eye Res 2010;90:679-87
95. Ueta M, Kinoshita S. Ocular surface inflammation is regulated by innate immunity. Progr Ret Eye Res 2012;31:551-75
96. Ulanova M, Duta F, Puttagunta L, et al. Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis. Expert Opin Ther Targets 2005;9(5):901-21
97. Malaviya R, Zhu D, Dibirdik I, et al. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J Biol Chem 1999;274(38):27028-38
98. Butrus S. Assessing the dry eye drug pipeline. Ophthalmol Manage 2013;17:30-4
99. Keane-Myers AM, Miyazaki D, Liu G, et al. Prevention of allergic eye disease by treatment with IL-1 receptor antagonist. Invest Ophthalmol Vis Sci 1999;40(12):3041-6
100. Amparo F, Dastjerdi MH, Okanobo A, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol 2013;131(6):715-23
101. Mantelli F, Lambiase A, Bonini S, et al. Clinical trials in allergic conjunctivitis: a systematic review. Allergy 2011;66:919-24